| Schedule of Earnings Per Share |
The following table presents the calculation of basic and diluted net loss per share for Class A and Class B common stock. No shares of Class C common stock were issued and outstanding during the periods presented. | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | 2026 | | 2025 | | Class A
Common | | Class B
Common | | Class A
Common | | Class B
Common | | (In thousands, except per share data) | | Numerator: | | | | | | | | Loss from continuing operations | $ | (1,787) | | | $ | (25) | | | $ | (3,794) | | | $ | (55) | | | Less: Accretion of Series A Preferred Stock to redemption value | (4,860) | | | (67) | | | (4,313) | | | (63) | | | Net loss attributable to Blend Labs, Inc. common stockholders from continuing operations | (6,647) | | | (92) | | | (8,107) | | | (118) | | | | | | | | | | | Net income (loss) attributable to Blend Labs, Inc. common stockholders from discontinued operations | 325 | | | 4 | | | (2,955) | | | (43) | | | | | | | | | | | Net loss attributable to Blend Labs, Inc. common stockholders | $ | (6,322) | | | $ | (88) | | | $ | (11,062) | | | $ | (161) | | | | | | | | | | | Denominator: | | | | | | | | | Weighted average common stock outstanding, basic and diluted | 236,653 | | | 3,256 | | | 255,484 | | | 3,727 | | | | | | | | | | | | | | | | | | | | | | | | | | | Net loss per share from continuing operations | | | | | | | | | Basic and diluted | $ | (0.03) | | | $ | (0.03) | | | $ | (0.03) | | | $ | (0.03) | | | Net income (loss) per share from discontinued operations | | | | | | | | | Basic and diluted | $ | 0.00 | | | $ | 0.00 | | | $ | (0.01) | | | $ | (0.01) | | | Net loss per share attributable to Blend Labs, Inc.: | | | | | | | | | Basic and diluted | $ | (0.03) | | | $ | (0.03) | | | $ | (0.04) | | | $ | (0.04) | |
| | | | | | | | | | | | | | | | | | | | | | | | | Six Months Ended June 30, | | 2026 | | 2025 | | Class A
Common | | Class B
Common | | Class A
Common | | Class B
Common | | (In thousands, except per share data) | | Numerator: | | | | | | | | Loss from continuing operations | $ | (7,181) | | | $ | (96) | | | $ | (10,591) | | | $ | (154) | | | Less: Accretion of Series A Preferred Stock to redemption value | (9,531) | | | (127) | | | (8,455) | | | (123) | | | Net loss attributable to Blend Labs, Inc. common stockholders from continuing operations | (16,712) | | | (223) | | | (19,046) | | | (277) | | | | | | | | | | | Net loss from discontinued operations | (2,225) | | | (30) | | | (5,718) | | | (83) | | Less: Accretion of RNCI to redemption value from discontinued operations | — | | | — | | | (1,236) | | | (18) | | | Less: Net loss attributable to noncontrolling interest included in discontinued operations | — | | | — | | | 179 | | | 3 | | | Net loss attributable to Blend Labs, Inc. common stockholders from discontinued operations | (2,225) | | | (30) | | | (6,775) | | | (98) | | | | | | | | | | | Net loss attributable to Blend Labs, Inc. common stockholders | $ | (18,937) | | | $ | (253) | | | $ | (25,821) | | | $ | (375) | | | | | | | | | | | Denominator: | | | | | | | | | Weighted average common stock outstanding, basic and diluted | 244,470 | | | 3,256 | | | 255,287 | | | 3,717 | | | | | | | | | | | | | | | | | | | | | | | | | | | Net loss per share from continuing operations | | | | | | | | | Basic and diluted | $ | (0.07) | | | $ | (0.07) | | | $ | (0.07) | | | $ | (0.07) | | | Net loss per share from discontinued operations | | | | | | | | | Basic and diluted | $ | (0.01) | | | $ | (0.01) | | | $ | (0.03) | | | $ | (0.03) | | | Net loss per share attributable to Blend Labs, Inc.: | | | | | | | | | Basic and diluted | $ | (0.08) | | | $ | (0.08) | | | $ | (0.10) | | | $ | (0.10) | |
|
| Schedule of Antidilutive Securities |
The following potential shares of common stock were excluded from the computation of diluted net earnings per share attributable to the Company for the periods presented because including them would have been antidilutive as the Company has reported net loss for each of the periods:
| | | | | | | | | | | | | | | | | As of June 30, | | | | 2026 | | 2025 | | | | | | (In thousands) | | | | | | Outstanding stock options | 14,494 | | | 16,314 | | | | | | | | | | | | | | | Non-plan Co-Founder and Head of Blend options | 20,194 | | | 20,194 | | | | | | | Unvested restricted stock units | 14,368 | | | 11,456 | | | | | | Unvested performance stock awards(1) | 7,627 | | | 8,435 | | | | | | | Series G Warrant | 598 | | | 598 | | | | | | | Haveli Warrant | — | | | 11,111 | | | | | | | Series A redeemable convertible preferred stock | 46,154 | | | 46,154 | | | | | | | Total anti-dilutive securities | 103,435 | | | 114,262 | | | | | |
____________ (1) Performance conditions were not satisfied for the unvested performance stock awards as of June 30, 2026.
|